Compare Nvidia Corp (NVDA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

NVIDIA (NVDA) trades at $228.52, up 0.97% with strong fundamental performance including 55.84% net profit margin and consistent earnings beats. The stock shows bullish technical signals with support at $225 and resistance at $228. Revenue growth accelerated to $130.5B in 2025, while analyst consensus remains strongly bullish with a $339.17 price target representing 48% upside potential.

NVIDIA's AI leadership and expanding market position support continued growth, though valuation multiples remain elevated. Key risks include increased competition and potential market saturation in AI chips. The company's strong cash flow generation and institutional support provide fundamental backing for long-term investors despite near-term volatility concerns.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.